Lercanidipina Sandoz

Lercanidipine Hydrochloride, the active ingredient in Lercanidipina Sandoz, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering peripheral vascular resistance.

GNH USA supplies Lercanidipina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker indicated for the management of high blood pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness

Serious or Rare Side Effects: - Severe hypotension - Hepatic dysfunction - Allergic reactions, including angioedema

Before initiating therapy, consider the following safety measures.

Blood pressure monitoring: measure baseline and periodic readings to assess response. Drug interactions: review concomitant medications, especially CYP3A4 inhibitors or inducers. Renal impairment: use with caution in patients with severe renal dysfunction. Pregnancy and lactation: avoid unless benefits outweigh potential risks, as safety data are limited. Store at ambient temperature: keep in the original container, protect from moisture and light.

Lercanidipine can interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Concomitant antihypertensives (e.g., other calcium‑channel blockers): risk of excessive hypotension.

Moderate Interactions (Monitor Closely): - Grapefruit juice: may modestly raise drug exposure. - Diuretics: may enhance orthostatic hypotension.